• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Corrigendum on "Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers".

作者信息

Ali Ayad M, Tofiq Ahmed M, Rostam Hassan M, Ali Kameran M, Tawfeeq Hassan M

机构信息

Department of Chemistry, University of Garmian, University Campus, Kalar, Kurdistan Region, Iraq.

Department of Biology, College of Education, University of Garmian, University Campus, Kalar, Kurdistan Region, Iraq.

出版信息

J Med Virol. 2023 May;95(5):e28824. doi: 10.1002/jmv.28824.

DOI:10.1002/jmv.28824
PMID:37226971
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10316981/
Abstract
摘要

相似文献

1
Corrigendum on "Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers".关于“与未接种疫苗者相比，感染SARS-CoV-2 Delta或Omicron变异株的患者中同源疫苗接种的疾病严重程度和疗效（以主要生物标志物为指标）”的勘误
J Med Virol. 2023 May;95(5):e28824. doi: 10.1002/jmv.28824.
2
Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.与未接种疫苗的患者相比，使用主要生物标志物比较感染 SARS-CoV-2 Delta 或 Omicron VOC 患者的疾病严重程度和同源疫苗接种效果。
J Med Virol. 2022 Dec;94(12):5867-5876. doi: 10.1002/jmv.28098. Epub 2022 Sep 9.
3
Comments on "Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers".关于“与未接种疫苗者相比，感染SARS-CoV-2 Delta或Omicron变异株的患者中同源疫苗接种的疾病严重程度和疗效，以主要生物标志物为依据”的评论
J Med Virol. 2023 May;95(5):e28822. doi: 10.1002/jmv.28822.
4
In response to: Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.回应：与未接种疫苗者相比，感染SARS-CoV-2 Delta或Omicron变异株的患者中同源疫苗接种的疾病严重程度和疗效，以主要生物标志物为依据
J Med Virol. 2023 Jan;95(1):e28213. doi: 10.1002/jmv.28213. Epub 2022 Oct 17.
5
Response to comments to the editor on "Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers".对编辑关于“与未接种疫苗者相比，感染SARS-CoV-2 Delta或Omicron变异株的患者中同源疫苗接种的疾病严重程度和疗效，以主要生物标志物为依据”的评论的回复
J Med Virol. 2023 May;95(5):e28820. doi: 10.1002/jmv.28820.
6
Reply to Letter to the Editor on disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.回复给编辑的信：关于与未接种疫苗者相比，感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）德尔塔或奥密克戎变异株的患者中同源疫苗接种的疾病严重程度和疗效，采用主要生物标志物进行分析
J Med Virol. 2023 Jan;95(1):e28313. doi: 10.1002/jmv.28313. Epub 2022 Nov 21.
7
Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2.未接种疫苗和接种疫苗的个体中感染原始、Delta 或奥密克戎 SARS-CoV-2 的传染性病毒载量。
Nat Med. 2022 Jul;28(7):1491-1500. doi: 10.1038/s41591-022-01816-0. Epub 2022 Apr 8.
8
Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.恢复期和接种疫苗血清对 SARS-CoV-2 原始株、Beta、Delta 和奥密克戎变异株临床分离株的免疫原性。
Med. 2022 Jun 10;3(6):422-432.e3. doi: 10.1016/j.medj.2022.04.002. Epub 2022 Apr 14.
9
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.mRNA COVID-19 疫苗 3 剂接种与 SARS-CoV-2 奥密克戎和德尔塔变异株引起的有症状感染之间的关联。
JAMA. 2022 Feb 15;327(7):639-651. doi: 10.1001/jama.2022.0470.
10
Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.疫苗对 Alpha、Delta 或奥密克戎变异株流行期间 SARS-CoV-2 再感染的有效性：一项丹麦全国性研究。
PLoS Med. 2022 Nov 22;19(11):e1004037. doi: 10.1371/journal.pmed.1004037. eCollection 2022 Nov.

引用本文的文献

1
A study on the side effects caused by the Pfizer/BioNTech COVID-19 vaccine: Focus on IgG antibodies and serological biomarkers.一项关于辉瑞/生物科技公司新冠疫苗引起的副作用的研究：聚焦于IgG抗体和血清生物标志物。
Cent Eur J Immunol. 2024;49(1):2-10. doi: 10.5114/ceji.2024.136382. Epub 2024 Apr 9.

本文引用的文献

1
Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.与未接种疫苗的患者相比，使用主要生物标志物比较感染 SARS-CoV-2 Delta 或 Omicron VOC 患者的疾病严重程度和同源疫苗接种效果。
J Med Virol. 2022 Dec;94(12):5867-5876. doi: 10.1002/jmv.28098. Epub 2022 Sep 9.
2
Challenges for modelling interventions for future pandemics.未来大流行疫情干预措施建模面临的挑战。
Epidemics. 2022 Mar;38:100546. doi: 10.1016/j.epidem.2022.100546. Epub 2022 Feb 11.
3
Serum troponin, D-dimer, and CRP level in severe coronavirus (COVID-19) patients.严重冠状病毒（COVID-19）患者的血清肌钙蛋白、D-二聚体和 C 反应蛋白水平。
Immun Inflamm Dis. 2022 Mar;10(3):e582. doi: 10.1002/iid3.582. Epub 2021 Dec 22.